Stephen Gehlbach to Osteoporosis, Postmenopausal
This is a "connection" page, showing publications Stephen Gehlbach has written about Osteoporosis, Postmenopausal.
Connection Strength
1.587
-
FitzGerald G, Compston JE, Chapurlat RD, Pfeilschifter J, Cooper C, Hosmer DW, Adachi JD, Anderson FA, D?ez-P?rez A, Greenspan SL, Netelenbos JC, Nieves JW, Rossini M, Watts NB, Hooven FH, LaCroix AZ, March L, Roux C, Saag KG, Siris ES, Silverman S, Gehlbach SH. Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab. 2014 Mar; 99(3):817-26.
Score: 0.434
-
Gehlbach SH, Avrunin JS, Puleo E, Spaeth R. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007 Jun; 18(6):805-10.
Score: 0.267
-
Gehlbach SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health. 2002 Feb; 92(2):271-3.
Score: 0.190
-
Compston JE, Flahive J, Hooven FH, Anderson FA, Adachi JD, Boonen S, Chapurlat RD, Cooper C, D?ez-Perez A, Greenspan SL, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Silverman S, Siris ES, Watts NB, Gehlbach SH. Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW). Calcif Tissue Int. 2014 Feb; 94(2):223-31.
Score: 0.109
-
D?ez-P?rez A, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Siris ES, Wyman A, Rushton-Smith SK, Watts NB. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res. 2014 Jan; 29(1):260-7.
Score: 0.108
-
Costa AG, Wyman A, Siris ES, Watts NB, Silverman S, Saag KG, Roux C, Rossini M, Pfeilschifter J, Nieves JW, Netelenbos JC, March L, LaCroix AZ, Hooven FH, Greenspan SL, Gehlbach SH, D?ez-P?rez A, Cooper C, Compston JE, Chapurlat RD, Boonen S, Anderson FA, Adachi JD, Adami S. When, where and how osteoporosis-associated fractures occur: an analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One. 2013; 8(12):e83306.
Score: 0.108
-
Tom SE, Adachi JD, Anderson FA, Boonen S, Chapurlat RD, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, Nieves JW, Pfeilschifter J, Roux C, Silverman S, Wyman A, LaCroix AZ. Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 2013 Mar; 61(3):327-34.
Score: 0.102
-
Greenspan SL, Wyman A, Hooven FH, Adami S, Gehlbach S, Anderson FA, Boone S, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Silverman S, Siris ES, Watts NB. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012 Mar; 60(3):455-61.
Score: 0.095
-
Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, D?ez-P?rez A, Lindsay R, Saag KG, Netelenbos JC, Gehlbach S, Hooven FH, Flahive J, Adachi JD, Rossini M, Lacroix AZ, Roux C, Sambrook PN, Siris ES. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011 Nov; 124(11):1043-50.
Score: 0.093
-
Hooven F, Gehlbach SH, Pekow P, Bertone E, Benjamin E. Follow-up treatment for osteoporosis after fracture. Osteoporos Int. 2005 Mar; 16(3):296-301.
Score: 0.056
-
Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, D?ez-P?rez A, Anderson FA, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Greenspan SL, Premaor M, Cooper C. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012 Jun; 50(6):1288-93.
Score: 0.024